Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 79,327 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Breast Cancer, Gynecologic Cancer
Interventions: Guided Lifestyle Program Intervention, Self-Guided Lifestyle Program (Control Arm); Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Multiple Sclerosis
Interventions: Teriflunomide, Placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 4
States / cities: Cullman, Alabama • Tampa, Florida • Boston, Massachusetts + 1 more

Conditions: Acne
Interventions: Duac, Ziana gel; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 12 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Louisville, Kentucky • Mason, Ohio

Conditions: Huntington's Disease
Interventions: Not listed
Lead sponsor: University College, London; Other
Eligibility: 11 Years to 75 Years
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2017
U.S. locations: 6
States / cities: Englewood, Colorado • Washington D.C., District of Columbia • Baltimore, Maryland + 3 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Paclitaxel, Gemcitabine, Avastin; Drug · Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pharmacogenomic Drug Interaction
Interventions: Panel-based pharmacogenetic genotyping; Diagnostic Test
Lead sponsor: University of Florida; Other
Eligibility: 40 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Prurigo Nodularis, Pruritis
Interventions: Vixarelimab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 40
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 33 more

Conditions: Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
Interventions: VGX-3100, Placebo, Electroporation (EP); Biological · Device
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 22
States / cities: Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more

Conditions: Fuchs' Dystrophy, Bullous Keratopathy
Interventions: Prednisolone acetate, Fluorometholone; Drug
Lead sponsor: Price Vision Group; Industry
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Parkinson Disease, Tremor
Interventions: Istradefylline Pill; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: McLean, Virginia

Conditions: Otitis Media
Interventions: PNCRM9, Placebo comparator; Biological
Lead sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 2
States / cities: Bloomington, Minnesota • Minneapolis, Minnesota

Conditions: Psoriasis
Interventions: SFA002; Drug
Lead sponsor: SFA Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Pompano Beach, Florida • Fargo, North Dakota • Philadelphia, Pennsylvania

Conditions: Obstructive Sleep Apnea, Spinal Cord Injuries
Interventions: Mild intermittent hypoxia, Sham protocol, Continuous positive airway pressure (CPAP); Other
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Detroit, Michigan

Conditions: Unilateral Traumatic Amputation, Amputation, Traumatic
Interventions: Powered ankle prosthesis, Dynamic Response Foot; Device
Lead sponsor: Deanna H Gates; Other
Eligibility: 21 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hepatitis C Virus Infection
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 23
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 20 more

Conditions: Reversible Cerebral Vasoconstriction Syndrome
Interventions: TCD- cerebral blood flow velocities, Headache pain score, Neurological examination, Repeat Neuroimaging, Nimodipine, Verapamil ER; Diagnostic Test · Behavioral · Other + 1 more
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Glioblastoma
Interventions: CART-EGFR-IL13Ra2 Cells; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2039
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line
Interventions: Avelumab, Irinotecan, Paclitaxel, Best Supportive Care (BSC); Drug · Other
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 28
States / cities: Denver, Colorado • Pueblo, Colorado • Miami, Florida + 24 more

Conditions: Dementia
Interventions: Oral Fasudil 90 mg/day, Oral Fasudil 180 mg/day, Oral Placebo; Drug
Lead sponsor: Woolsey Pharmaceuticals; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Stamford, Connecticut • Lakeland, Florida • Miami Lakes, Florida + 3 more

Conditions: Teen Pregnancy Prevention
Interventions: Are You Ready? (AYR), Social Media Awareness Shorts (SMAS); Behavioral
Lead sponsor: The Policy & Research Group; Other
Eligibility: 14 Years to 22 Years
Enrollment: 1,850 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Body Weight
Interventions: Message; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dry Eye Disease
Interventions: Lotemax, Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears), In Vivo Confocal Microscopy (IVCM); Drug · Diagnostic Test
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: transdermal nicotine patch (7mg); Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 45 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 2 Diabetes
Interventions: SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) Test and SomaSignal Metabolic Factors test; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 40 Years to 89 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Avanzando Juntas: Adapting an Evidence Based Weight Loss Program for Hispanic Breast Cancer Survivors

Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis

Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne

HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer

Trial of Precision Medicine in Emergency Departments

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)

Istradefylline Effect Protocol on Parkinson's Disease Tremor

Maternal Immunization To Prevent Infant Otitis Media

Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques

Mild Intermittent Hypoxia and Its Multipronged Effect on Sleep Apnea

Determining the Potential Benefit of Powered Prostheses

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection

RCVS: The Rational Approach to Diagnosis and Treatment

CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Fasudil fOr redUcing elopemeNt and Spatial Disorientation

Evaluation of Are You Ready?

Messages and Plans to Increase Gym Utilization

The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED

Nicotine Patch, Blood Flow and Oxidative Stress Study

Pragmatic Impact of Proteomic Risk Stratification in Diabetes Mellitus